About selpercatinib
Selective RET kinase inhibitor
Used for
- RET fusion-positive non-small cell lung cancer
- RET-mutant medullary thyroid cancer
- RET fusion-positive thyroid cancer
- Other advanced RET-altered solid tumors
Usual adult dose
160 mg by mouth twice daily, adjusted for side effects and drug interactions.
Usual dose in children
For patients aged 2 years and older: 92 mg/m² by mouth twice daily, maximum 160 mg per dose.
Common side effects
- High blood pressure
- Liver enzyme increases
- Diarrhea
- Dry mouth and fatigue
Important warnings
- Can cause liver injury; liver tests are monitored.
- May cause high blood pressure or abnormal heart rhythm.
- Can impair wound healing; treatment may need pausing before surgery.
- Can harm an unborn baby; effective contraception is needed.
Pregnancy
May cause fetal harm. Avoid during pregnancy; hormonal contraception may be less reliable during treatment and for one week afterward.
Breastfeeding
Do not breastfeed during treatment and for one week after the final dose.
Interactions
- Strong or moderate CYP3A inhibitors can raise selpercatinib levels.
- CYP3A inducers can lower levels and reduce effectiveness.
- May reduce effectiveness of hormonal contraceptives.
- Acid-reducing medicines can reduce absorption; timing or treatment changes may be needed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.